CureVac (NASDAQ:CVAC) Reaches New 1-Year Low – Here’s What Happened

CureVac N.V. (NASDAQ:CVAC)’s stock price reached a new 52-week low on Monday . The company traded as low as $4.01 and last traded at $4.0650, with a volume of 576889 shares. The stock had previously closed at $4.16.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CureVac in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.83.

CureVac Stock Down 2.3%

The business has a 50 day moving average of $5.20 and a two-hundred day moving average of $5.30. The stock has a market capitalization of $911.93 million, a PE ratio of 5.65 and a beta of 1.77. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70.

CureVac (NASDAQ:CVAC) last released its quarterly earnings results on Monday, November 24th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07. CureVac had a net margin of 199.92% and a negative return on equity of 23.03%. The business had revenue of $63.53 million during the quarter, compared to analyst estimates of $21.40 million. Analysts predict that CureVac N.V. will post 0.72 EPS for the current year.

Hedge Funds Weigh In On CureVac

A number of large investors have recently made changes to their positions in CVAC. Caitong International Asset Management Co. Ltd boosted its position in shares of CureVac by 354.8% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock worth $30,000 after purchasing an additional 4,375 shares in the last quarter. Headlands Technologies LLC acquired a new position in CureVac during the 2nd quarter valued at about $35,000. Integrated Wealth Concepts LLC raised its stake in CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after buying an additional 3,000 shares during the last quarter. Kathmere Capital Management LLC acquired a new stake in CureVac in the second quarter worth about $60,000. Finally, L2 Asset Management LLC purchased a new stake in shares of CureVac during the second quarter worth about $70,000. 17.26% of the stock is owned by institutional investors and hedge funds.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.